Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167642 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1AALDH1A1ITGB3ITGA2B | |
| SCHEMBL10855149 | 0.96 | SMN1; SMN2 (0.47) | SMN1; SMN2HIF1AALDH1A1ITGB3ITGA2B | |
| SCHEMBL10855143 | 0.96 | SMN1; SMN2 (0.47) | SMN1; SMN2HIF1AALDH1A1ITGB3ITGA2B | |
| SCHEMBL27484782 | 0.96 | SMN1; SMN2 (0.47) | SMN1; SMN2HIF1AALDH1A1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL31300266 | 0.93 | ALDH1A1 (0.44) | SMN1; SMN2HIF1AALDH1A1ITGB3ITGA2B | |
| SCHEMBL8427346 | 0.90 | ALDH1A1 (0.41) | SMN1; SMN2HIF1AALDH1A1ITGB3ITGA2B | |
| SCHEMBL9629603 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1AALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL27618465 | 0.89 | ALDH1A1 (0.41) | SMN1; SMN2HIF1AALDH1A1ITGB3ITGA2B | |
| SCHEMBL5711297 | 0.89 | GRM2 (0.48) | SMN1; SMN2HIF1AALDH1A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL13518879 | 0.87 | ALDH1A1 (0.42) | ALDH1A1ITGB3ITGA2BMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090023-A1 | A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND, AND RELATED METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-05-01 | — | — | WO | disclosed |
| CN-114787192-B | Single domain antibodies targeting Prostate Specific Membrane Antigen (PSMA) | 国家生物技术研究所公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-4355371-A1 | HISTIDINE-SELECTIVE POLYMER REAGENTS | Nektar Therapeutics (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022266498-A1 | HISTIDINE-SELECTIVE POLYMER REAGENTS | NEKTAR THERAPEUTICS (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-1021175-B1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CT (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8431527-B2 | Methods for alleviating deleterious effects of 3-deoxyglucosone | FOX CHASE CANCER CENTER (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110112188-A1 | Treatment of Inflammatory Conditions | DYNAMIS THERAPEUTICS, INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110034522-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | THE INSTITUTE FOR CANCER RESEARCH | 2011-02-10 | — | — | US | disclosed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | DYNAMIS THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-1021175-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000040577-A1 | 1-CARBOXYMETHYL-2-OXO-AZEPAN DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF MMP-12 | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999064561-A2 | METHOD FOR ASSESSING A DIABETIC'S RISK OF EXPERIENCING A DIABETES-ASSOCIATED PATHOLOGIC CONDITION | FOX CHASE CANCER CENTER (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998033492-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5496805-A | DIURETIC, HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1996-03-05 | — | — | US | disclosed |
| EP-0541742-A1 | 2',5'-NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992021691-A1 | 2',5'-NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1992-12-10 | — | — | WO | disclosed |
| US-4849414-A | HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1989-07-18 | — | — | US | disclosed |
| US-4565653-A | Acyltripeptide immunostimulants | PFIZER INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4187217-A | HYPOTENSIVE AGENT OF PROLONGED EFFECT | CHIPENS GUNAR I (SU) | 1980-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034522-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | AGER, ALDOA, FBP1 | SMN1; SMN2 4651/4885HIF1A 2149/4885ALDH1A1 472/4885 |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | FN3K, ROS1, FN3KRP | SMN1; SMN2 4499/4885HIF1A 462/4885ALDH1A1 1848/4885 |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DPM1, G6PD, UGGT1 | SMN1; SMN2 3746/4885HIF1A 328/4885ALDH1A1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.